EXPERIENCE OF APPLICATION OF ANTI PD-1 THERAPY IN MMR-DEFICIENCY ENDOMETRIAL CANCER
https://doi.org/10.18027/2224-5057-2018-8-2-60-63
Abstract
Currently, more and more studies show the effectiveness of anti-PD-1 therapy in tumors with a deficiency of the unpaired DNA nucleotide repair system (MMR). According to various sources in endometrial cancer, the MMR deficit is determined in 20–30 % of cases. This paper presents the experience of successful immunotherapy (anti PD-1) in a patient with metastatic endometrioid adenocarcinoma of the uterus with a deficiency of MMR.
About the Authors
K. G. Cham
Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov
Russian Federation
Russian Federation
Karine G. Cham - MD, Oncologist, PhD student, Postgraduate.
St. Petersburg
G. A. Raskin
Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov; Saint Petersburg State Research Institute of Phthisiopulmonology; Saint Petersburg State University
Russian Federation
Russian Federation
Grigory A. Raskin - MD, DSc Med, Head of the Immunohistochemistry Laboratory, RRC RST named after Academician A. M. Granov; Senior Researcher, SPS RIP; Professor of the Department of Oncology, MF, SPSU
T. T. Andabekov
AV Medical Group
Russian Federation
Russian Federation
Timur T. Andabekov - MD, Oncologist, AV Medical Group.
St. Petersburg
M. K. Rodina
Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov
Russian Federation
Russian Federation
Mariya K. Rodina - Researcher, Scientific Group of Molecular Genetic Prognosis and Individualization of Treatment.
St. Petersburg
I. O. Rutkin
Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov
Russian Federation
Russian Federation
Igor O. Rutkin - MD, Oncologist, Department of Minimally Invasive Surgery.
St. Petersburg
D. M. Kondrachuk
Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov
Russian Federation
Russian Federation
Dmitry M. Kondrachuk - MD, Radiologist, Department of Computed Tomography.
St. Petersburg
V. L. Vinokurov
Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov
Russian Federation
Russian Federation
Vladimir L. Vinokurov - MD, DSc Med, Professor, Honoured Worker of Science, Head of the Department of Radiosurgical Gynecology, RRCRST named after Academician A. M. Granov; Member of the European Society of Gynecologists and Oncologists; Member of the New York Academy of Sciences.
St. Petersburg
References
1. Weiderpass E., Labreche F. Malignant tumors of the female reproductive system. Saf. Health Work. 2012. Vol. 3. P. 166–180.
2. Bray F., Loos A. H., Oostindier M., Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. Int. J. Cancer. 2005. Vol. 117. P. 123–131.
3. Liu F. S. Molecular carcinogenesis of endometrial cancer. Taiwan J. Obstet. Gynecol. 2007. Vol. 46. P. 26–32.
4. Tinelli A., Mezzolla V., Leo G., Pisano M., Storelli F., Alemanno G. et al. Microsatellite instability (MSI) as genomic markers in endometrial cancer: toward scientific evidences. Mini Rev. Med. Chem. 2010. Vol. 10. P. 1356–1365.
5. Weigelt B., Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr. Opin. Oncol. 2012. Vol. 24. P. 554–563.
6. Haruko K., Kouji B. et al. New use of microsatellite instability analysis in endometrial cancer (Review). Oncol. Lett. 2017. Vol. 14 (3). P. 3297–3301. Published online on: July 20, 2017.
7. Karamurzin Y., Rutgers J. K. DNA mismatch repair deficiency in endometrial carcinoma. Int. J. Gynecol. Pathol. 2009. Vol. 28. P. 239–255.
8. Murali R., Soslow R. A., Weigelt B. Classification of endometrial carcinoma: More than two types. Lancet Oncol. 2014. Vol. 15. P. e268–e278.
9. Aksel’ E. M. Statistika zlokachestvennykh novoobrazovanii zhenskikh polovykh organov (Statistics of malignant new growths of female genitals). Opukholi zhenskoi reproduktivnoi sistemy (Tumors of female reproductive system). 2012. No. 1-2. P. 76–80 (In Russ.).
10. Meyer L. A., Broaddus R. R., Lu K. H. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009. Vol. 16. P. 14–22.
11. Zaanan A., Meunier K., Sangar F., Flejou J. F., Praz F. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell. Oncol. (Dordr.). 2011. Vol. 34. P. 155–176.
12. Karamurzin Y., Zeng Z., Stadler Z. K., Zhang L., Ouansafi I., Al-Ahmadie H. A. et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum. Pathol. 2012. Vol. 43. P. 1677–1687.
13. Leenen C. H., van Lier M. G., van Doorn H. C., van Leerdam M. E., Kooi S. G., de Waard J. et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer 70 years. Gynecol. Oncol. 2012. Vol. 125. P. 414–420.
14. Van Lier M. G., Wagner A., van Leerdam M. E., Biermann K., Kuipers E. J., Steyerberg E. W. et al. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J. Cell. Mol. Med. 2010. Vol. 14. P. 181–197.
15. Schneider R., Schneider C., Kloor M., Furst A., Moslein G. Lynch syndrome: clinical, pathological, and genetic insights. Langenbecks Arch. Surg. 2012. Vol. 397. P. 513–525.
16. Bartley A. N., Luthra R., Saraiya D. S., Urbauer D. L., Broaddus R. R. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev. Res. (Philadelphia). 2012. Vol. 5. P. 320–327.
17. Le D. T., Uram J. N., Wang H., Bartlett B. R. et al. PD-1 Blockade in tumors with mismatch- repair deficiency. N. Engl. J. Med. 2015. Vol. 372 (26). P. 2509–2520.
Review
For citations:
Cham K.G., Raskin G.A., Andabekov T.T., Rodina M.K., Rutkin I.O., Kondrachuk D.M., Vinokurov V.L. EXPERIENCE OF APPLICATION OF ANTI PD-1 THERAPY IN MMR-DEFICIENCY ENDOMETRIAL CANCER. Malignant tumours. 2018;8(2):60-63. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-2-60-63
Views:
1016
Email this article 